NYSEAMERICAN:STXS

Stereotaxis - STXS Stock Forecast, Price & News

$1.88

0.00 (0.00%)

(As of 10/5/2022 01:16 PM ET)

Add

Compare

Today's Range: $1.85
▼
$1.88
50-Day Range: N/A
52-Week Range: $1.72
▼
$7.22

Volume: 491 shs
Average Volume: 165,192 shs
Market Capitalization: $140.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.40

Stereotaxis MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 346.8% Upside
$8.40 Price Target
Short Interest: Bearish
2.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.24) to ($0.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Stereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.40, Stereotaxis has a forecasted upside of 346.8% from its current price of $1.88.
Amount of Analyst Coverage
Stereotaxis has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.53% of the float of Stereotaxis has been sold short.
Short Interest Ratio / Days to Cover
Stereotaxis has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Stereotaxis has recently increased by 15.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Stereotaxis does not currently pay a dividend.
Dividend Growth
Stereotaxis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for STXS.

2.7

News and Social Media Coverage

News Sentiment
Stereotaxis has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Stereotaxis this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for STXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stereotaxis insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.16% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
48.74% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Stereotaxis are expected to grow in the coming year, from ($0.24) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stereotaxis is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stereotaxis is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stereotaxis has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Stereotaxis (NYSEAMERICAN:STXS) Stock

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

STXS Stock News Headlines

October 3, 2022 | globenewswire.com

Stereotaxis Receives St. Louis Mayor's Innovation Award for - GlobeNewswire

October 3, 2022 | finance.yahoo.com

Stereotaxis Receives St. Louis Mayor’s Innovation Award for 2022

September 29, 2022 | globenewswire.com

International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value - GlobeNewswire

September 29, 2022 | finance.yahoo.com

International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value

September 24, 2022 | globenewswire.com

Electrophysiology Market is expected to generate a revenue of USD 10.70 Billion by 2028, Globally, at 10.26% CAGR: Verified Market Research - GlobeNewswire

September 17, 2022 | fool.com

Stereotaxis (NYSEMKT: STXS)

September 13, 2022 | benzinga.com

Stereotaxis (AMEX:STXS) – Overland Park Regional Medical Center Extends Leadership in Robotic Treatment o - Benzinga

September 13, 2022 | globenewswire.com

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System - GlobeNewswire

September 8, 2022 | finance.yahoo.com

Medical Automation Market Size, Share, Competitive Analysis, Growth Status, Top Players and Market Is Projected To Reach 93,734.64 Million By 2028 - Yahoo Finance

August 29, 2022 | finance.yahoo.com

The Global Robotic Medical Imaging Systems Market is expected to grow by $ 621.24 mn during 2022-2026, accelerating at a CAGR of 14.1% during the forecast period - Yahoo Finance

August 26, 2022 | reuters.com

STXS.K - Stereotaxis Inc | Stock Price & Latest News | Reuters

August 11, 2022 | businesswire.com

Global Cardiovascular Imaging Equipment Pipeline Report 2022 - ResearchAndMarkets.com - Business Wire

August 11, 2022 | streetinsider.com

Form 10-Q Stereotaxis, Inc. For: Jun 30 - StreetInsider.com

August 10, 2022 | finance.yahoo.com

Stereotaxis (STXS) Q2 2022 Earnings Call Transcript

August 9, 2022 | finance.yahoo.com

Stereotaxis Inc. (STXS) Reports Q2 Loss, Misses Revenue Estimates

August 9, 2022 | benzinga.com

Recap: Stereotaxis Q2 Earnings - Benzinga

August 9, 2022 | globenewswire.com

Stereotaxis Reports 2022 Second Quarter Financial Results - GlobeNewswire

August 9, 2022 | finance.yahoo.com

Stereotaxis Reports 2022 Second Quarter Financial Results

August 8, 2022 | seekingalpha.com

Stereotaxis Q2 2022 Earnings Preview (NYSE:STXS) - Seeking Alpha

August 6, 2022 | nasdaq.com

Orthofix (OFIX) Beats Q2 Earnings and Revenue Estimates - Nasdaq

August 2, 2022 | finance.yahoo.com

The Global Metaverse in Fashion Market is expected to grow by $ 6.61 bn during 2022-2026, accelerating at a CAGR of 36.47% during the forecast period - Yahoo Finance

August 2, 2022 | globenewswire.com

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline - GlobeNewswire

August 2, 2022 | finance.yahoo.com

Industry Veterans Join Stereotaxis Commercial Leadership Team as Company Advances Robust Innovation Pipeline

July 20, 2022 | bizjournals.com

Channeling Elon Musk: How St. Louis CEO David Fischel's pay package channels the Tesla founder, but carries risks. - The Business Journals

July 19, 2022 | globenewswire.com

Stereotaxis to Report Second Quarter Financial Results on August 9, 2022 - GlobeNewswire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

STXS Company Calendar

Last Earnings: 8/09/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:STXS
CUSIP: N/A
CIK: N/A
Web: www.stereotaxis.com
Phone: (314) 678-6100
Fax: 314-678-6159
Employees: 130
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.40
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +346.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,720,000.00
Net Margins: -56.30%
Pretax Margin: -56.30%
Return on Equity: -52.64%
Return on Assets: -29.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.42
Quick Ratio: 2.85

Sales & Book Value

Annual Sales: $35.02 million
Price / Sales: 4.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.45 per share
Price / Book: 4.18

Miscellaneous

Outstanding Shares: 74,790,000
Free Float: 60,460,000
Market Cap: $140.61 million
Optionable: Optionable
Beta: 1.68

Key Executives

Dr. David Leo Fischel C.A.I.A. (Age 35)
C.F.A., C.P.A., M.B.A., CFA, CPA, CEO & Chairman
Comp: $62.2k

Ms. Kimberly R. Peery
CFO & Sec.

Mr. Keith Galloway
VP of Operations

Ms. Laura Spencer Garth
Gen. Counsel

John Platt
Sr. Director of Project Management & Systems Software

Nathan Kastelein
R&D Leader and Sr. Director of R&D and Advanced Concepts

Brian Kidd
R&D Leader and Sr. Director of Product Devel.

Mr. Guy Judkowski
Equity Portfolio Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STXS Stock - Frequently Asked Questions

Should I buy or sell Stereotaxis stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STXS shares.
View STXS analyst ratings or view top-rated stocks.
What is Stereotaxis' stock price forecast for 2022?: 4 analysts have issued twelve-month price objectives for Stereotaxis' stock. Their STXS share price forecasts range from $6.00 to $13.00. On average, they predict the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 346.8% from the stock's current price.
View analysts price targets for STXS or view top-rated stocks among Wall Street analysts.
How have STXS shares performed in 2022?: Stereotaxis' stock was trading at $5.51 at the beginning of 2022. Since then, STXS shares have decreased by 65.9% and is now trading at $1.88.
View the best growth stocks for 2022 here.
When is Stereotaxis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our STXS earnings forecast.

How were Stereotaxis' earnings last quarter?: Stereotaxis, Inc. (NYSEAMERICAN:STXS) issued its earnings results on Tuesday, August, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The firm earned $6.15 million during the quarter, compared to analyst estimates of $7.60 million. Stereotaxis had a negative trailing twelve-month return on equity of 52.64% and a negative net margin of 56.30%.
What is Stereotaxis' stock symbol?: Stereotaxis trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "STXS."
How do I buy shares of Stereotaxis?: Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Stereotaxis' stock price today?: One share of STXS stock can currently be purchased for approximately $1.88.
How much money does Stereotaxis make?: Stereotaxis (NYSEAMERICAN:STXS) has a market capitalization of $140.61 million and generates $35.02 million in revenue each year. The company earns $-10,720,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.
How many employees does Stereotaxis have?: The company employs 130 workers across the globe.
How can I contact Stereotaxis?: Stereotaxis' mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The official website for the company is www.stereotaxis.com. The company can be reached via phone at (314) 678-6100, via email at investors@stereotaxis.com, or via fax at 314-678-6159.

This page (NYSEAMERICAN:STXS) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Stereotaxis - STXS Stock Forecast, Price & News

Stereotaxis MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month